Olmesartan 5/40 mg Tablet
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Dongsung Pharmaceuticals Co., Ltd.
MFDS item code 201904377 · Approved 2019.06.26
This product's status changed to Expired on 2024.06.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to treat patients with essential hypertension who do not achieve adequate blood pressure control with monotherapy of amlodipine or olmesartan medoxomil. Essential hypertension is a condition characterized by persistently high blood pressure, placing strain on the heart and blood vessels, and it is crucial to manage it appropriately. This medication effectively lowers blood pressure, reducing the risk of cardiovascular complications. Regular monitoring of blood pressure control during treatment is necessary. It is designed for ease of ingestion, helping to manage blood pressure without interfering with daily life, ultimately leading to improved health through stable blood pressure control.
Administer 1 tablet once daily with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before administering this drug; however, switching directly to this drug may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to a fetus and a newborn baby if taken during pregnancy, particularly in the second and third trimesters. If pregnancy is confirmed, discontinue use immediately. Patients with allergies to the ingredients in this medication, those who are pregnant or breastfeeding, those with severely impaired liver or kidney function, or those with certain heart conditions should not use this medication. Patients with reduced fluid or sodium may experience hypotension; therefore, careful observation is required at the start of treatment, and appropriate action should be taken if hypotension occurs. Rarely, vasodilation may cause a sudden drop in blood pressure; thus, caution is needed, especially for patients with heart valve diseases. Patients with weakened heart or kidney function may experience worsening of kidney function when taking this medication, and regular testing is required. This medication may cause various side effects, including dizziness, headaches, hypotension, dyspepsia, rashes, and edema. Patients experiencing abnormal symptoms should consult a doctor. This medication may interact with other drugs, so patients must inform their doctor or pharmacist of any other medications they are taking. It is safer to avoid use during pregnancy, and if breastfeeding, it is recommended to discontinue either nursing or the medication as it may pass into breast milk. Safety and efficacy in children and adolescents under 18 years old have not been established; therefore, use is not recommended. Elderly patients may have higher concentrations of the medication in their body due to decreased kidney function, necessitating dosage adjustments and caution. In case of overdose, symptoms such as hypotension and cardiac arrhythmias may occur, requiring immediate medical treatment. Store this medication in a tightly closed container away from moisture and heat, out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication over time.
Light yellow round film-coated tablet
30 tablets (10 tablets/PTP X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Dongsung Pharmaceuticals Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.